Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock
Key stats
- Market cap
- $2.20B
- Price / Earnings ratio
- -5.2x
- EPS (TTM)
- -$5.90
- Volume
- Loading
- 52-week high
- $56.05
- 52-week low
- $26.38
Source: third-party data provider, as of November 13, 2026
Compare with VERA
Recent news

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
VERA

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
VERA

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
VERA

US FDA approves Vera's kidney disease drug
US FDA approves Vera's kidney disease drug
VERA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 50.46
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.23
- MACD histogram
- 0.16
- SMA 50
- $31.38
- Price below SMA 50
- EMA 50
- $31.14
- Price below EMA 50
- SMA 200
- $36.31
- Price below SMA 200
- EMA 200
- $36.07
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$1.16 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
Vera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
VERA

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
VERA

Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
VERA

US FDA approves Vera's kidney disease drug
US FDA approves Vera's kidney disease drug
VERA

3 Biotech Firms With Major Potential Catalysts in the Coming Months
3 Biotech Firms With Major Potential Catalysts in the Coming Months
VERA

3 Biotech Firms With Major Potential Catalysts in the Coming Months
3 Biotech Firms With Major Potential Catalysts in the Coming Months
VERA

$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
$20 Billion: Inside Nvidia's VERA CPU Bet to Break the Intel-AMD Duopoly
VERA

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment
VERA

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
VERA

This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
VERA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Vera Therapeutics, Inc. Class A Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, CEO & Director | 1975 |
| Mr. Sean P. Grant M.B.A. | Chief Financial Officer | 1985 |
| Mr. David L. Johnson M.B.A. | Chief Opearating Officer | 1970 |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer | 1968 |
| Mr. Joseph R. Young M.B.A. | Senior VP of Finance & Chief Accounting Officer | 1972 |
| Ms. S. Sandra Park J.D. | Senior VP of Legal, Healthcare,Commercial Law, Compliance & Operations | — |
| Dr. Jane Wright-Mitchell J.D., Pharm.D. | Chief Legal Officer & Secretary | 1969 |
| Ms. Debra Charlesworth | Vice President of Corporate Communications | — |
| Ms. Emma Haywood | Vice President of Marketing | — |
| Mr. Tom Doan | Executive Vice President of Development Operations | 1972 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 50.46
- MACD 12/26/9
- -0.07
- EMA 9 of MACD
- -0.23
- MACD histogram
- 0.16
- SMA 50
- $31.38
- Price below SMA 50
- EMA 50
- $31.14
- Price below EMA 50
- SMA 200
- $36.31
- Price below SMA 200
- EMA 200
- $36.07
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $29.00
- Average
- $57.40
- High
- $83.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +53.0 | -19.7 | ||||||||||
| 2022 | -29.0 | +15.4 | +2.7 | -12.5 | -27.8 | -2.9 | +30.0 | +27.7 | -0.4 | -8.7 | -8.9 | +18.3 |
| 2023 | -53.7 | -12.5 | +4.9 | -12.0 | +20.1 | +79.3 | +18.1 | -7.3 | -26.1 | -19.5 | +24.0 | +11.1 |
| 2024 | +133.3 | +23.9 | -12.3 | -6.7 | -10.2 | -10.2 | +0.8 | +0.5 | +15.2 | -5.7 | +13.5 | -14.7 |
| 2025 | -11.7 | -18.1 | -15.5 | +6.1 | -20.2 | -25.8 | -9.6 | +3.3 | +28.5 | -1.1 | +30.1 | +53.5 |
| 2026 | -11.0 | -9.9 | -0.5 | -12.1 | +0.9 | +26.4 | -24.8 | +5.7 | -5.7 | -0.0 | -0.7 |



